


Poland | Systemic analgesics

- Stablemate **APAP** (paracetamol) posted strong value growth during the Covid-19 pandemic; volume sales saw a surge in 2020, before declining in 2021
- Extensive product range – including nighttime (+ diphenhydramine) and Extra (+ caffeine) presentations – was extended with APAP Intense tablets (paracetamol 500mg, ibuprofen 200mg) in October 2020, claimed to provide a stronger analgesic effect and work for up to 8 hours
- TV ads for APAP Intense emphasised efficacy against severe pain & inflammation for up to 8 hours



- APAP Migrena (paracetamol 250mg, aspirin 250mg, caffeine 65mg) launched in July 2021; positioned to combat headache and migraine (with or without aura) in adults, it competes directly with Haleon's **Excedrin MigraStop** (\$1.9mn, +17%, CAGR +10%), the only other entry with this formula in Poland at the time of launch

Poland leading systemic analgesics mid-2022 (MSP, \$mn)					
	Brand	\$mn	mid-22/ mid-21	21/19	CAGR 21/17
1	Ibuprom (USP Zdrowie)	57.5	+19%	+12%	+6%
2	APAP (USP Zdrowie)	44.8	+11%	+25%	+8%
3	Nurofen (Reckitt)	23.5	+33%	-5%	+1%
4	Ibum (Hasco Lek)	18.2	+45%	+15%	+8%
5	Pyralgina (Polpharma)	15.2	+4%	+45%	+14%
6	Solpadeine (Perrigo)	12.2	+18%	+30%	+14%
7	Ketonal (Sandoz / Novartis)	11.7	+9%	+15%	+98%
8	Polopiryna S (Polpharma)	6.6	+11%	+20%	+4%
9	Etopiryna (Polpharma)	6.0	-2%	+1%	+0%
10	Dexak (Berlin-Chemie / Menarini)	5.3	+8%	+1%	+0%
11	Ibufen (Polpharma)	5.2	+83%	-11%	-4%
12	Gripex Control (USP Zdrowie)	5.0	+22%	+19%	+5%
13	Opokan (Aflofarm)	4.5	+2%	+31%	+10%
14	Bayer Aspirin (Bayer)	3.8	-5%	+4%	+0%
	Private labels	3.4	+41%	+24%	+22%
	Others	43.8	+19%	+19%	+6%

Germany | Topical analgesics

- ThermaCare regularly contributes to good causes: in early 2022 it collaborated with Terre des Femmes to highlight violence against women, donating €2 (\$2.21) from every purchase of ThermaCare bei Regelschmerzen in March-April to the women's rights organisation; in late 2022 every purchase helped support four German Red Cross (DRK) cold aid projects for the homeless


- Previous A+P initiatives included offering a free 3-month subscription to Liebscher & Bracht pain therapists app, and in 2021 cashback coupons for larger SKUs in pharmacies and online



- Comfrey-based **Kytta** benefits from rising demand for natural options; TV ads for brand since 2020 feature tagline “The power of nature against pain”, showing a woman able to play with her grandchildren in the forest again after Kytta relieves her back pain (*see below*)

Germany topical analgesics sales by medicated / non-medicated presentations 2021 (MSP, \$mn)



Medicated 52%
(+3%, CAGR +0%)



Non-medicated 48%
(+3%, CAGR +2%)

Non-medicated segment comprises brands without traditional allopathic ingredient (NSAIDs, paracetamol, metamizole, etc.) and includes brands with menthol

Germany topical analgesics sales by format 2021 (MSP, \$mn)




TV ads feature odourless option Kytta Geruchsneutral

- From March-June 2022, consumers could receive a €2 (\$2.21) discount on core Kytta Schmerzsalbe, the bestselling format
- Previous A+P claimed that Kytta is “as strong as diclofenac ointment”, emphasising trials claiming it offers comparable relief to diclofenac

France | Mouth & dental analgesics

France mouth & dental analgesics sales mid-2021 & mid-2022 (MSP, \$mn)



Sales reflect MAT for 12-month period ending June 2021 & 2022
Growth rates are % change on previous 12 months

Key trends & developments

- Topline sales flat, with leading brands struggling for growth; No.1 brand Camilia has perhaps been impacted by ongoing questions around the role and efficacy of homeopathy
- Segments for teething pain (led by Camilia) and relief of oral pain (led by Pansoral)
- Brands here face new competition from EG / Stada's SyntholOral, an extension of popular topical analgesic brand Synthol / SyntholKiné

- Homeopathic **Camilia** maintains its dominant position thanks to TV, print and online ads stressing suitability for teething in babies; promotion carries the tagline “Camilia, to soothe baby during teething”
- No.2 brand in the teething pain segment is Gilbert's **Dolo** range, which includes **Dologel** (medical device; chamomile, propolis, valerian) and **Dolodent** (OTC; amyleine hydrochloride) but receives little consumer promotion
- In October 2020 Gilbert extended its mouth & dental analgesics portfolio with **Dentinéa** homeopathic teething remedy (1ml unidose vials) to tackle pain redness and excess salivation
- Both positioned for oral pain and ulcers, **Pansoral** (cetalkonium chloride, choline salicylate) and **Hyalugel** (sodium hyaluronate) compete closely for the No.2 spot, although there was little A+P support for either brand; Pierre Fabre also fields **Elgydium** (cosmetics and medical devices; for teething and ulcers)



Brazil | Herbal & natural joint health supplements

- Promotion for Condres included the Virtual Condres Run held in May 2021; for every 1,000 athletes that took part in the run, EMS donated 100 units of Condres to people in care homes
- The event was publicised via social media with the hashtag #CorraPorEles (RunForThem)
- Continuing with the sports focus, in September 2022 Condres Performa (NCT-II, BCAA, CoQ10, vitamins & minerals), to increase performance and physical power, was launched
- Launched in 2020, Trio (hydrolysed collagen, non-hydrolysed type II collagen, MSM, vitamins & minerals) is now the biggest-selling presentation of 2016 launch **Colflex**



- Colflex Muscular soluble powder (hydrolysed collagen, hydroxymethylbutyrate, vitamin D; to help synthesis of muscle mass and reduce muscle degradation) and Colflex Hialu tablets (Bioiberica's b-2Cool non-hydrolysed type II collagen, Mobbilee – a natural extract rich in hyaluronic acid, polysaccharides and collagen – plus MSM; for joint function and lubrication of synovial fluid) launched in 2021



- Like Condres, Colflex is supported by promotion to HCPs and to consumers via social media

Brazil leading herbal & natural joint health supplements mid-2022 (MSP, \$mn)					
	Brand	\$mn	mid-22/ mid-21	21/19	CAGR 21/17
1	Condres (EMS / NC Farma)	22.2	+29%	+24%	+13%
2	Colflex (Mantecorp / Hypera Pharma)	16.1	+36%	+172%	+79%
3	Motilex (Apsen)	11.8	+6%	+41%	+41%
4	Artrogen Duo (Aché)	4.6	-15%	-18%	+77%
5	Disfor / Trifor (Biolab)	4.3	+4%	-6%	-4%
6	Protena (Aché)	3.9	+7%	+16%	n/a
7	Extima (Apsen)	3.7	+21%	+23%	+31%
8	Cartigen (FQM / Roemmers)	3.3	+14%	+96%	+16%
9	Equaliv Cartliv (Althaia)	2.6	-11%	-20%	n/a
10	Mobility Artiflex (Sanofi)	1.9	-17%	-30%	-21%
	Others	25.9	+41%	+90%	+37%